A peer group of researchers and investigators investigated the effect of thymoquinone with different doses (2 and 4 mg/kg) dose‐dependently against MDA‐MB‐231 triple negative breast cancer in experimental mouse via inhibiting CXCR4 expression, tumor growth, and tumor vascularity along with suppressing the brain, lung, and bone metastases. Here, CXCR4 is linked to triple-negative breast carcinoma.